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the number of patients achieving major molecular and complete cytogenetic re-
sponses. Fewer patients treatedwith nilotinib progressed to advance or blast phase
than with imatinib. The objective of this analysis was to assess, from a HK societal
perspective, the cost and quality-adjusted-life-years (QALYs) of imatinib versus
nilotinib in newly-diagnosed Ph CML-CP. METHODS: A literature-based Markov
model was developed to estimate the lifetime QALYs and costs of typical 47 year-
old CML-CP patients initiating first-line (FL) therapy. Two periods were considered:
the first year, reflecting the ENESTnd data, and all subsequent years (until all pa-
tients had died/reached 100 years), based on stratified disease progression data
from the International Randomized Study of Interferon and STI571 (IRIS) study.
Patients who discontinued FL therapy were modeled to receive one additional
tyrosine kinase inhibitor (TKI). Prognosis after FL therapy discontinuation was
modeled using published studies. Local demographics and costs were used to pop-
ulate themodel. Quality of lifewas assumed to vary by disease stage and treatment
status (on/off TKI). The threshold used to define a cost-effective therapy was the
WHO’s 3 x GDP/capita (i.e., HKD247,712; USD31,758; USD1  HKD7.8). RESULTS:
Compared to imatinib, nilotinib results in a gain of 2.32 life years and 2.30 QALYs.
The cost/life year gain was HKD156,042 (USD20,005) and incremental cost/ QALY
was HKD157,313 (USD20,168). Univariate sensitivity analysis showed results were
generally robust. Key drivers were the duration of analysis, discount rates, age at
therapy initiation, and inclusion/exclusion of indirect costs. In probabilistic sensi-
tivity analysis, 95% of model replications cost HKD 180,000 (USD23,077)/QALY
gained. CONCLUSIONS: Using local and non-local data, this analysis suggests that
nilotinib is cost-effective compared to imatinib as FL treatment for CML-CP pa-
tients from a HK societal perspective.
PCN58
A COMPREHENSIVE COST-EFFECTIVENESS ANALYSIS OF LENALIDOMIDE FOR
MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR
THERAPY
Félix J, Almeida J, Vandewalle B
Exigo Consultores, Alhos Vedros, Setúbal, Portugal
OBJECTIVES: Guidelines preferred (category 1) salvage therapies for relapsed/re-
fractory multiple myeloma typically include bortezomib (BTZ) and lenalidomide.
Since no randomized controlled trials (RCT) or relative effectiveness assessments
comparing both drugs exist a comprehensive assessment of the cost-effectiveness
of lenalidomidedexamethasone (LEN/DEX) was performed in different drug se-
quencing (1 prior vs. 1 prior therapy) using indirect comparison. METHODS: A
Markov-type model was designed to assess long-term cost-effectiveness of LEN/
DEX vs BTZ (indirect), using patient-level data from the MM-009/MM-010 RCTs
(LEN/DEX vs. DEX) and published APEX trial data (BTZ vs. DEX). Due to potential
crossover-induced bias, overall survival (OS) was estimated using a quantitative
relationship between time-to-progression/progression-free-survival and OS (cen-
sored normal weighted Tobit regression model, based on 153 studies containing
230 treatment arms and 22,696 MM patients). The indirect comparison was based
on a mixed treatment comparison of time-to-progression from the aforemen-
tioned trials. The Portuguese societal perspective was assumed. Effectiveness was
measured in life years (LY) and quality-adjusted life years (QALY). Annual discount
rates were set at 5%. Probabilistic sensitivity analysis was conducted with Monte-
Carlo simulations. RESULTS: LEN/DEX is estimated to add substantial clinical ben-
efits to BTZ. In patients with1 prior therapy incremental LY, QALY and costs with
LEN/DEX were 1.1 LY (95%CI: 0.4;2.0), 0.8 QALY (95%CI: 0.3;1.5) and 49,266€ (95%CI:
37,730€;67,342€) and in patients with only 1 prior therapy 1.4 LY (95%CI: 0.4;2.9), 1.1
QALY (95%CI: 0.3;2.1) and 57,293€ (95%CI: 39,303€;84,809€), respectively. Corre-
sponding ICERs (LEN/DEX vs BTZ) ranged from 39,770€/LY to 61,649/QALY.
CONCLUSIONS: Lenalidomide plus dexamethasone can be regarded as a cost-ef-
fective choice compared to bortezomib monotherapy for relapsed/refractory mul-
tiple myeloma patients in Portugal.
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OBJECTIVES: Renal cell carcinoma (RCC) is a prevalent form of kidney cancer and is
associated with a poor prognosis. Less than 10% of patients with advanced or
metastatic disease (mRCC) survive beyond 5 years. Recently introduced therapies
are associated with significant clinical improvements over standard treatments
such as interferon alfa (IFN). The objective of this research was to evaluate the
cost-effectiveness of novel first line treatments for mRCC under the Brazilian Pub-
lic Health System perspective.METHODS: A Markov model was designed to simu-
latemRCCprogression,mortality and associated costs. Themodelwas evaluated in
a period of 2 years. A systematic review of the literature was conducted on the
efficacy and safety of pazopanib, sunitinib, and bevacizumab associated to INF in
patients treated for mRCC. Costs and consequences of the disease treatment were
computed for each targeted alternative. Only direct medical costs were considered
and reported in 2011 Brazilian currency (1BRL0.60USD). Costs and outcomeswere
discounted at 5% yearly. Outcomes assessed were progression-free survival (PFS)
and quality adjusted life years (QALY). Stochastic simulations tested model
robustness. RESULTS: No direct comparison studies were found evaluating the
efficacy of the alternatives. Thus, an indirect comparison was applied in order to
determine the relative efficacy of each therapy. The indirect PFS hazzard ratio (95%
CI) suggests that pazopanib is not statistically different from sunitinib (0.93 [0.56,
1.56]) or bevacizumabIFN (0.79 [0.48, 1.32]). Estimated QALYs were 0.93 for
sunitinib, 0.90 for pazopanib, and 0.88 for bevacizumabINF. The incremental
cost-effectiveness ratio (ICER) revealed that sunitinib costs about R$245,000 per
QALY gained compared to pazopanib. BevacizumabINF was dominated across
all scenarios. Sensitivity analysis confirmed the base case results. CONCLUSIONS:
Pazopanib reported lower costs and similar benefits across studied comparators as
first line treatment of patients diagnosed with mRCC under the Brazilian public
perspective.
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OBJECTIVES: To evaluate economics of nilotinib 600 mg and dasatinib 100 mg,
compared to imatinib 400 mg, as first line therapy in chronic myeloid leukemia in
Colombia, from third payer perspective.METHODS: Amarkov model used to eval-
uate 100 patients, aged 55 years, with newly diagnosed CML in chronic phase, in a
10 year time horizon. Progression free life years saved (PF-LYS)were considered the
analysis outcome. Transition probabilitieswere analyzed in themodel according to
literature review. A 3% discount rate was applied to costs and outcomes. In the
absence of any head to head trials to compare nilotinib and dasatinib, comparisons
were made independently for each one versus imatinib. Costs analysis included
direct medical costs obtained from local health care providers databases at prices
for year 2011. Transplantation costs were excluded. Prices for medicines were es-
timated from official government top reimbursement prices. There was a univari-
ate and multivariate Montecarlo sensibility analysis. RESULTS: Nilotinib was
greater expected PF-LYS (15,376 vs. 14,643 for Imatinib), followed by Dasatinib
(15,108 vs. 14,789 for Imatinib). Imatinib had lower total lifetime costs. The incre-
mental cost-effectiveness ratio (ICER) was USD $6.828 per PF-LYS in the Nilotinib
arm and USD $32.501 per PF-LYS for Dasatinib arm, each compared to Imatinib.
When analyzing indirectly Nilotinib vs. Dasatinib, Nilotinib was found to be dom-
inant due to higher efficacy (267,65 PF-LYS) and less costs (USD $5.290) in the base
case. The multivariate sensitivity analysis showed that Nilotinib maintained its
dominance against Imatinib and Dasatinib in most scenarios. The average esti-
mated cost to manage disease progression per three months was USD $ 17.335
which was considered as threshold. CONCLUSIONS: From a third party payer per-
spective in Colombia, using PF-LYS, nilotinib is highly cost-effective when com-
pared to imatinib and dominant vs dasatinib in first line therapy for CML in chronic
phase.
PCN61
COST-EFFECTIVENESS OF SUNITINIB  BEST SUPPORTIVE CARE FOR THE
TREATMENT OF UNRESECTABLE PANCREATIC NEUROENDOCRINE TUMORS IN
MEXICO
Chi-Chan A1, Gutiérrez-Colín CI1, Peniche-Otero G2, Herrera-Rojas J2, Muciño E1,
Galindo-Suárez RM1
1Pfizer S.A. de C.V., Mexico City, Mexico, 2Customized Premium Products S.A. de C.V., Mexico
City, Mexico
OBJECTIVES: Patients with non-resectable pancreatic Neuroendocrine Tumors
(NET) have very few therapeutic alternatives. Sunitinib had showed a substantial
clinical benefit in this group of patients, however there are few economic studies
pursuing to estimate its economic consequences. The objective of this studywas to
estimate the cost-effectiveness of sunitinib in the treatment of well-differentiated
non-resectable pancreatic NET, from the perspective of the Social SecurityMexican
Institute (IMSS).METHODS: A three health states Markov model (pre-progression,
post-progression, death; 2-week cycles) was used to estimate the health and eco-
nomic consequences of sunitinib 37.5/day best supportive care (BSC) regarding
placebo BSC along a ten-years horizon (discount rate: 5%). Effectiveness mea-
sures were overall: survival (OS), progression-free survival (PFS) and quality ad-
justed life years gained (QALY). Resource utilization (BSC, adverse events manage-
ment, medical follow up) was estimated through a Delphi Panel with Mexican
oncologists (n10). Unit costs of medication and medical resources were obtained
from institutional sources. Deterministic and probabilistic sensitivity analyses
were developed and acceptability curves were constructed. RESULTS:
SunitinibBSC gained additional 0.49 years of PFS, 1.18 years of OS and 0.70 QALYs
against placeboBSC. SunitinibBSC increasedmedical direct costs (2011 US$) per
patient in $20,854 (around two-fold the cost of placeboBSC: $18,082), which was
driven by acquisition costs of sunitinib and medical follow up before progression
(due to the noted clinical benefit in sunitinib’s patients). ICER’s were $42,157,
$17,662 and $29,808 per progression-free year, life-year and QALY gained, respec-
tively, which remained robust through25% changes inmain parameters. At will-
ingness to pay higher than $40,000, $21,800 and $37,200 sunitinibBSC becomes
the most efficient alternative in regards to PFS, OS and QALYs, respectively.
CONCLUSIONS:At IMSS, sunitinibBSCwould provide substantial clinical benefits
to patients suffering unresectable pancreatic NET, although the latter would in-
crease medical costs of treatment and clinical follow up.
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